Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Citi
Accenture
Harvard Business School
Cantor Fitzgerald
Covington
Federal Trade Commission
Medtronic
Express Scripts

Generated: June 19, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021598

« Back to Dashboard

NDA 021598 describes VIGAMOX, which is a drug marketed by Novartis Pharms Corp and is included in one NDA. It is available from six suppliers. There are two patents protecting this drug and one Paragraph IV challenge. Additional details are available on the VIGAMOX profile page.

The generic ingredient in VIGAMOX is moxifloxacin hydrochloride. There are eighteen drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the moxifloxacin hydrochloride profile page.
Summary for 021598
Tradename:VIGAMOX
Applicant:Novartis Pharms Corp
Ingredient:moxifloxacin hydrochloride
Patents:2
Therapeutic Class:Antibacterials
Formulation / Manufacturing:see details
Pharmacology for NDA: 021598
Ingredient-typeQuinolones
Suppliers and Packaging for NDA: 021598
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VIGAMOX moxifloxacin hydrochloride SOLUTION/DROPS;OPHTHALMIC 021598 NDA Alcon Laboratories, Inc. 0065-4013 N 0065-4013-01
VIGAMOX moxifloxacin hydrochloride SOLUTION/DROPS;OPHTHALMIC 021598 NDA Alcon Laboratories, Inc. 0065-4013 N 0065-4013-03

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION/DROPS;OPHTHALMICStrengthEQ 0.5% BASE
Approval Date:Apr 15, 2003TE:AT1RLD:Yes
Patent:➤ Sign UpPatent Expiration:Mar 29, 2020Product Flag?Substance Flag?Delist Request?Y
Patent:➤ Sign UpPatent Expiration:Mar 29, 2020Product Flag?Substance Flag?Delist Request?Y

Expired US Patents for NDA 021598

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms Corp VIGAMOX moxifloxacin hydrochloride SOLUTION/DROPS;OPHTHALMIC 021598-001 Apr 15, 2003 ➤ Sign Up ➤ Sign Up
Novartis Pharms Corp VIGAMOX moxifloxacin hydrochloride SOLUTION/DROPS;OPHTHALMIC 021598-001 Apr 15, 2003 ➤ Sign Up ➤ Sign Up
Novartis Pharms Corp VIGAMOX moxifloxacin hydrochloride SOLUTION/DROPS;OPHTHALMIC 021598-001 Apr 15, 2003 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Cerilliant
UBS
Harvard Business School
Chinese Patent Office
US Department of Justice
US Army
Mallinckrodt
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.